AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19618688 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolytic iron fortified wheat flour
Number of subjects: 400
Study 19618688 — intervention group
Group type: COMPARATOR
Intervention: Non-fortified flour (control)
Number of subjects: 400
Study 17329296 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 63
Study 17329296 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotics (CA)
Number of subjects: 63
Study 17329296 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine and CA
Number of subjects: 63
Study 15554315 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaccine 'Bubo-Kok'
Number of subjects: 0
Study 11447364 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT oil (60 g daily for 2 weeks)
Number of subjects: 12
Study 11447364 — intervention group
Group type: COMPARATOR
Intervention: LCT (corn oil, 56 g daily for 2 weeks)
Number of subjects: 12
Study 8694324 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (3 micrograms/kg increments)
Number of subjects: 23
Study 8694324 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 23
Study 8694324 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 23
Study 1306672 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Precision toothbrush
Number of subjects: 151
Study 1306672 — intervention group
Group type: COMPARATOR
Intervention: Oral-B 40 toothbrush
Number of subjects: 151
Study 1306672 — intervention group
Group type: COMPARATOR
Intervention: Reach Full-Head soft toothbrush
Number of subjects: 151
Study 4009848 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral vertebral operations
Number of subjects: 109
Study 4009848 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific operative procedures (subclavian-vertebral roof-patch angioplasty, reimplantation, carotid-vertebral vein bypass, decompression)
Number of subjects: 109
Study 4009848 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologic complications
Number of subjects: 109
Study 31204328 — intervention group
Group type: EXPERIMENTAL
Intervention: General dental practitioners (GDPs)
Number of subjects: 188
Study 31204328 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-practicing molar endodontics
Number of subjects: 188
Study 31204328 — intervention group
Group type: EXPERIMENTAL
Intervention: Referring difficult cases to endodontists
Number of subjects: 188
Study 31204328 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital single visit root canal treatment
Number of subjects: 188
Study 31204328 — intervention group
Group type: EXPERIMENTAL
Intervention: Necrotic single visit root canal treatment
Number of subjects: 188
Study 31204328 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber dam isolation
Number of subjects: 188
Study 31204328 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized preparation technique
Number of subjects: 188
Study 31204328 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-setting calcium hydroxide as intra-canal medicament
Number of subjects: 188
Study 31204328 — intervention group
Group type: EXPERIMENTAL
Intervention: Delaying final restoration
Number of subjects: 188
Study 29551340 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine offered in the intervention group
Number of subjects: 109
Study 29551340 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccine offered)
Number of subjects: 109
Study 28163478 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 40
Study 28163478 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 40
Study 28163478 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA)
Number of subjects: 40
Study 28163478 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 25048955 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led interventions (follow-up by a specialist nurse after 3 months)
Number of subjects: 459
Study 25048955 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 459
Study 23013352 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (80 mg/day)
Number of subjects: 38
Study 23013352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 19945816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive telephone counseling (bi-weekly)
Number of subjects: 360
Study 19945816 — intervention group
Group type: COMPARATOR
Intervention: Less intensive telephone counseling (monthly)
Number of subjects: 360
Study 17643971 — intervention group
Group type: EXPERIMENTAL
Intervention: Central tendency measure (CTM)
Number of subjects: 187
Study 17643971 — intervention group
Group type: EXPERIMENTAL
Intervention: CTM
Number of subjects: 187
Study 17643971 — intervention group
Group type: COMPARATOR
Intervention: Classical indexes (ODIs and CT90)
Number of subjects: 187
Study 17643971 — intervention group
Group type: COMPARATOR
Intervention: Indexes derived from approximate entropy (ApEn)
Number of subjects: 187
Study 16097274 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward allocations by kindergartners
Number of subjects: 112
Study 16097274 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward allocations by older participants (3rd grade, 9th grade, college)
Number of subjects: 112
Study 16097274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fairness ratings
Number of subjects: 112
Study 12389338 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg 3 times a day for 12 days (administered on day 8 before digoxin)
Number of subjects: 11
Study 12389338 — intervention group
Group type: COMPARATOR
Intervention: Digoxin 0.75 mg (administered alone)
Number of subjects: 11
Study 12389338 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated steady-state peak levels of digoxin with acarbose
Number of subjects: 11
Study 12389338 — intervention group
Group type: COMPARATOR
Intervention: Simulated steady-state peak levels of digoxin without acarbose
Number of subjects: 11
Study 12389338 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated steady-state trough (Cmin,ss) and average (Cave,ss) concentrations
Number of subjects: 11
Study 10430713 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of deep inspiration during methacholine challenge
Number of subjects: 10
Study 10430713 — intervention group
Group type: COMPARATOR
Intervention: Initial methacholine challenge with DIs
Number of subjects: 10
Study 10430713 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of deep inspiration after three doses of methacholine
Number of subjects: 10
Study 10430713 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of deep inspiration after four doses of methacholine
Number of subjects: 10
Study 7556961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy
Number of subjects: 1347
Study 7556961 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 1347
Study 7556961 — intervention group
Group type: COMPARATOR
Intervention: Intensive treatment
Number of subjects: 1347
Study 1934686 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of hyaluronic acid administered intra-articularly once a week for 3 weeks
Number of subjects: 0
Study 1934686 — intervention group
Group type: COMPARATOR
Intervention: 40 mg of 6-methylprednisolone acetate administered intra-articularly once a week for 3 weeks
Number of subjects: 0
Study 6179650 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibromodulcitol 10 mg/kg PO weekly for 8 weeks plus bleomycin 15 mu/m2 (initially three times weekly, later changed to twice weekly for 8 weeks)
Number of subjects: 62
Study 6179650 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin 15 mu/m2 (initially three times weekly, later changed to twice weekly for 8 weeks)
Number of subjects: 62
Study 30912836 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained inflations (up to 2 sustained inflations at maximal peak pressure of 25 cm H2O for 15 seconds); n=215
Number of subjects: 426
Study 30912836 — intervention group
Group type: COMPARATOR
Intervention: Standard intermittent positive pressure ventilation; n=211
Number of subjects: 426
Study 30912836 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained inflations; n=215
Number of subjects: 426
Study 29417850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger root powder (0.5 g, 2 capsules per day, 0.25 g per capsule, every 12 hours for 5 days)
Number of subjects: 140
Study 29417850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 29417850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger root powder
Number of subjects: 140
Study 27100399 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic arabinoxylan oligosaccharides (AXOS) 10 g twice daily
Number of subjects: 39
Study 27100399 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 39
Study 27100399 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic arabinoxylan oligosaccharides (AXOS)
Number of subjects: 39
Study 24500725 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 489
Study 24500725 — intervention group
Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy
Number of subjects: 489
Study 22313047 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C8*3 allele
Number of subjects: 161
Study 22313047 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C8*4 allele
Number of subjects: 161
Study 22313047 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C8*2 allele
Number of subjects: 161
Study 22313047 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C8*3 and CYP2C8*4 alleles
Number of subjects: 161
Study 22313047 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C8 variants
Number of subjects: 161
Study 22313047 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C8 variants in the Czech population
Number of subjects: 161
Study 19398072 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous standardised extract of kava
Number of subjects: 60
Study 19398072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17985945 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 15
Study 17985945 — intervention group
Group type: COMPARATOR
Intervention: No Hormone Replacement Therapy (Control)
Number of subjects: 15
Study 14981335 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Hypericum perforatum extract WS 5570 (600, 900, and 1,200 mg)
Number of subjects: 12
Study 14981335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11574227 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal models of ischemia and ex vivo reperfusion
Number of subjects: 249
Study 11574227 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial measures of outcome
Number of subjects: 249
Study 11574227 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical transplantation studies
Number of subjects: 249
Study 11574227 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials
Number of subjects: 249
Study 9827425 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (0.5%‐1 cc) every 12 h + Placebo every 12 h
Number of subjects: 50
Study 9827425 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide with Salbutamol
Number of subjects: 50
Study 7816287 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (1.25 and 2.5 ng.kg‐1 min‐1)
Number of subjects: 25
Study 7816287 — intervention group
Group type: COMPARATOR
Intervention: Control group (lithium carbonate 750 mg, 20 mmol)
Number of subjects: 25
Study 3075724 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine 150 mg/day
Number of subjects: 16
Study 3075724 — intervention group
Group type: EXPERIMENTAL
Intervention: Metapramine 450 mg/day
Number of subjects: 16
Study 3075724 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 16
Study 30468528 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic cuff (5 cm wide) applied to one arm at 10% and 20% of resting length
Number of subjects: 35
Study 30468528 — intervention group
Group type: COMPARATOR
Intervention: Pressurized nylon cuff (5 cm wide) inflated to 40% and 80% of resting arterial occlusion pressure
Number of subjects: 35
Study 27309340 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured discharge information
Number of subjects: 3
Study 25661111 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver education level (completed high school)
Number of subjects: 423
Study 25661111 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's dental visits
Number of subjects: 423
Study 25661111 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver education level
Number of subjects: 423
Study 23227676 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart-kidney acupuncture group
Number of subjects: 111
Study 23227676 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture group
Number of subjects: 111
Study 20945740 — intervention group
Group type: EXPERIMENTAL
Intervention: Bur-prepared restorations
Number of subjects: 27
Study 20945740 — intervention group
Group type: COMPARATOR
Intervention: Laser-prepared restorations
Number of subjects: 27
Study 17630271 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation (CR) programme
Number of subjects: 49
Study 17630271 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based cardiac rehabilitation (CR) programme
Number of subjects: 49
Study 17630271 — intervention group
Group type: EXPERIMENTAL
Intervention: General reasons for non-adherence
Number of subjects: 49
Study 16131498 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 162
Study 16131498 — intervention group
Group type: COMPARATOR
Intervention: Control (non-intervention assessment-only)
Number of subjects: 162
Study 12362923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg once daily with food
Number of subjects: 652
Study 12362923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg once daily without food
Number of subjects: 652
Study 12362923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study 11125744 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined movements of the hand and foot in individuals with paraplegia
Number of subjects: 0
Study 11125744 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined movements of the hand and foot in individuals with quadriplegia
Number of subjects: 0
Study 11125744 — intervention group
Group type: COMPARATOR
Intervention: Imagined movements of the hand and foot in able-bodied controls
Number of subjects: 0
Study 11125744 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined movements of the foot in individuals with paraplegia
Number of subjects: 0
Study 11125744 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined movements of the foot in individuals with quadriplegia
Number of subjects: 0
Study 11125744 — intervention group
Group type: COMPARATOR
Intervention: Imagined movements of the foot in able-bodied controls
Number of subjects: 0
Study 11125744 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement and imagery ERPs comparison
Number of subjects: 0
Study 11125744 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined movements of paralyzed limbs
Number of subjects: 0
Study 7480677 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial phase (HAP) helical CT
Number of subjects: 103
Study 7480677 — intervention group
Group type: COMPARATOR
Intervention: Portal venous phase (PVP) helical CT
Number of subjects: 103
Study 7480677 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-phase acquisition
Number of subjects: 103
Study 2089926 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (2 mg per hour intravenously for 7 days)
Number of subjects: 352
Study 2089926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 444345 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 0.2 mg kg‐1
Number of subjects: 60
Study 444345 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 0.6 mg kg‐1
Number of subjects: 60
Study 444345 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 1.0 mg kg‐1
Number of subjects: 60
Study 444345 — intervention group
Group type: EXPERIMENTAL
Intervention: hexafluorenium 0.3 mg kg‐1 with suxamethonium 1.0 mg kg‐1
Number of subjects: 60
Study 444345 — intervention group
Group type: EXPERIMENTAL
Intervention: hexafluorenium 0.3 mg kg‐1
Number of subjects: 60
Study 444345 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 0.2 mg kg‐1 and 0.6 mg kg‐1 with or without hexafluorenium
Number of subjects: 60
Study 31406051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 1 mg·kg‐1
Number of subjects: 75
Study 31406051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg·kg‐1
Number of subjects: 75
Study 31406051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg·kg‐1
Number of subjects: 75
Study 29547835 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib (1.5 mg/day orally; 3 weeks on/1 week off)
Number of subjects: 162
Study 29547835 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (previous treatment)
Number of subjects: 162
Study 26803690 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet (target, 50mmol/24 h)
Number of subjects: 23
Study 24690305 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up condition
Number of subjects: 731
Study 22642858 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum personality traits (positive emotionality, negative emotionality, and constraint) and past-year psychopathology (anxiety, mood, and substance use disorder) as predictors.
Number of subjects: 1365
Study 22642858 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative emotionality
Number of subjects: 1365
Study 22642858 — intervention group
Group type: COMPARATOR
Intervention: Psychopathology (anxiety, mood, and substance use disorder)
Number of subjects: 1365
Study 22642858 — intervention group
Group type: COMPARATOR
Intervention: Substance use disorder and constraint
Number of subjects: 1365
Study 22642858 — intervention group
Group type: COMPARATOR
Intervention: No single variable
Number of subjects: 1365
Study 20502377 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium prostheses (Ti)
Number of subjects: 0
Study 20502377 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyapatite prostheses (HA)
Number of subjects: 0
Study 20502377 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium and Hydroxyapatite prostheses
Number of subjects: 0
Study 18397445 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Care Model (CCM) for obesity
Number of subjects: 107
Study 18397445 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 107
Study 16084809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral psychotherapy and cognitive remediation, 50 minutes each, 3 times a week for 11 weeks.
Number of subjects: 20
Study 16084809 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-listed, received treatment after follow-up).
Number of subjects: 20
Study 12641387 — intervention group
Group type: EXPERIMENTAL
Intervention: New‐RH (S‐group)
Number of subjects: 16
Study 12641387 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (C‐group)
Number of subjects: 16
Study 10941863 — intervention group
Group type: EXPERIMENTAL
Intervention: Bombesin
Number of subjects: 8
Study 10941863 — intervention group
Group type: COMPARATOR
Intervention: Bombesin + atropine
Number of subjects: 8
Study 10941863 — intervention group
Group type: COMPARATOR
Intervention: Bombesin + somatostatin
Number of subjects: 8
Study 8528637 — intervention group
Group type: COMPARATOR
Intervention: HFX RT to a total dose of 64.8 Gy (Group 1)
Number of subjects: 169
Study 8528637 — intervention group
Group type: EXPERIMENTAL
Intervention: HFX RT with chemotherapy (100 mg carboplatin on days 1 and 2 and 100 mg etoposide on days 1-3 each week during RT) (Group 2)
Number of subjects: 169
Study 8528637 — intervention group
Group type: EXPERIMENTAL
Intervention: HFX RT with chemotherapy (200 mg carboplatin on days 1 and 2 and 100 mg etoposide on days 1-5 of the first, third, and fifth weeks) (Group 3)
Number of subjects: 169
Study 12283016 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (Mifepristone) 200 mg/day for 2 days before surgery
Number of subjects: 46
Study 12283016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 7297145 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA)
Number of subjects: 14
Study 7297145 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (DPY)
Number of subjects: 14
Study 7297145 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ASA and DPY (ASA-DPY)
Number of subjects: 14
Study 7297145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30711853 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 22
Study 30711853 — intervention group
Group type: COMPARATOR
Intervention: Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT)
Number of subjects: 22
Study 28960867 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical presentation at first HF hospitalization
Number of subjects: 193
Study 28960867 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior HF hospitalization
Number of subjects: 193
Study 28960867 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis therapy
Number of subjects: 193
Study 28960867 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular end‐diastolic volume >240 mL
Number of subjects: 193
Study 26422331 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote telementored (RTM)
Number of subjects: 12
Study 26422331 — intervention group
Group type: COMPARATOR
Intervention: Unmentored (UTM)
Number of subjects: 12
Study 26422331 — intervention group
Group type: COMPARATOR
Intervention: Surgeons
Number of subjects: 12
Study 22964761 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial letter fluency training
Number of subjects: 0
Study 22964761 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonemic switching training
Number of subjects: 0
Study 22964761 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0